Coconut Creek, FL, Feb 13, 2019 - (ACN Newswire) - via NEWMEDIAWIRE -- NutraFuels, Inc. ("NutraFuels"), soon to be NutraLife BioScience, Inc., has acquired a patent for a unique and natural formulation that deters insects including mosquitoes through a dermal delivery system patch. On January 28, 2019, NutraFuels founded a new wholly owned subsidiary, NutraDerma Technologies, Inc. ("NutraDerma") to commercialize the patented dermal patch.
The all-natural insect deterrent dermal patch is the first planned product for NutraDerma. The patented patch uses natural ingredients such as Vitamin B1 to ward off insects. NutraFuels founded NutraDerma to commercialize the all-natural dermal mosquito patch upon compliance with applicable regulatory requirements.
NutraDerma plans to develop other nutraceutical, skin care, cosmetic and wellness dermal skin patches including vitamin supplement patches and various formulations designed to harness the benefits of combining key ingredients and technologies to support health and wellness. With the acquisition of its new patent, NutraDerma has taken its first step towards entering the bio life sciences market.
According to the American Mosquito Control Association ("AMCA"), there are more than one million Malaria-related deaths and 300 - 500 million cases are reported annually throughout the world. As the Center for Disease Control ("CDC") reports, Zika is still a threat internationally as well.
NutraFuels, Inc. (USNQB:NUFT) is a fully reporting company with a class of securities registered with the U.S. Securities & Exchange Commission ("SEC"). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU's filings with the SEC can be viewed at www.sec.gov. NTFU's CBD products and information about the company's direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.
* These statements have not been evaluated by the Food and Drug Administration.
* This product is not intended to diagnose, treat, cure or prevent any disease.
Forward Looking Statements
This communication contains statements of a forward-looking nature about NutraFuels, Inc. fka NutraLife BioSciences, Inc., and its wholly owned subsidiary, NutraDerma Technologies, Inc. (the "Company"). These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as "may," "will," "except," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "future" or other similar expressions. The Company has based these forward-looking statements largely on the Company's current expectations and projections about future events and financial trends that the Company believes may affect Company's financial condition, results of operations, business strategy, and financial needs. There is no assurance that Company's current expectations and projections concerning its ability to commercialize the patented insect dermal patch are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company's management to predict all risk factors, nor can the Company assess the impact of all factors on Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Topic: Press release summary
Sectors: Food & Beverage, BioTech, Healthcare & Pharm, Funds & Equities, Cosmetics & Spec.Chem
From the Asia Corporate News Network
Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|NutraLife Biosciences, Inc. Releated News|
|Apr 12, 2019 07:20 HKT/SGT|
|NutraLife Biosciences, Inc. enters Joint Venture with Henning Trading LLC to Cultivate and Process Hemp for 2019 U.S. Grow Season|
|Apr 4, 2019 05:00 HKT/SGT|
|NutraLife Bioscience, Inc. Reports 2018 Year End Financial Results|
|Mar 25, 2019 05:00 HKT/SGT|
|NutraLife Biosciences Encouraged By CVS Health Corporation's Decision to Distribute CBD at 800 Stores in the U.S.|
|Mar 15, 2019 05:00 HKT/SGT|
|NutraLife Bioscience, Inc. Receives License to Grow and Process Industrial Hemp|
|Mar 13, 2019 05:00 HKT/SGT|
|NutraLife Biosciences, Inc. Receives Contract to Provide Its Technologies and Delivery System for Pharmaceutical Products by cGMP Pharmacy|
|More news >>|